A Study to Investigate the Efficacy and Safety of Rilzabrutinib in Adult Participants With Graves' Disease
Conditions
Graves' Disease
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Investigational Site Number : 1240003, Calgary, Alberta, Canada
Investigational Site Number : 1240002, Surrey, British Columbia, Canada
Investigational Site Number : 1240001, Sherbrooke, Quebec, Canada
Investigational Site Number : 2760002, Essen, Germany
Investigational Site Number : 2760001, Frankfurt, Germany
Investigational Site Number : 3800005, Merano, Bolzano / Bozen, Italy
Investigational Site Number : 3800001, Milan, Milano, Italy
Investigational Site Number : 3800004, Milan, Milano, Italy
Investigational Site Number : 3800003, Palermo, Italy
Investigational Site Number : 3800002, Pisa, Italy
Investigational Site Number : 7240002, Barcelona, Catalunya [Cataluña], Spain
Investigational Site Number : 7240001, Pamplona, Navarre, Spain
Investigational Site Number : 7240004, Seville, Sevilla, Spain
Investigational Site Number : 8260003, Milton Keynes, Buckinghamshire, United Kingdom
Investigational Site Number : 8260001, Newcastle upon Tyne, England, United Kingdom